Literature DB >> 27776266

Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages.

Paulina R Davis1, Ginevra Giannini2, Karin Rudolph2, Nathaniel Calloway3, Christopher M Royer2, Tina L Beckett3, M Paul Murphy4, Frederick Bresch5, Dieter Pagani6, Thomas Platt4, Xiaohong Wang3, Amy Skinner Donovan3, Tiffany L Sudduth7, Wenjie Lou3, Erin Abner3, Richard Kryscio3, Donna M Wilcock8, Edward G Barrett2, Elizabeth Head9.   

Abstract

Beta-amyloid (Aβ) immunotherapy is a promising intervention to slow Alzheimer's disease. Aging dogs naturally accumulate Aβ and show cognitive decline. An active vaccine against fibrillar Aβ 1-42 (VAC) in aged beagles resulted in maintenance but not improvement of cognition along with reduced brain Aβ. Behavioral enrichment (ENR) led to cognitive benefits but no reduction in Aβ. We hypothesized cognitive outcomes could be improved by combining VAC with ENR in aged dogs. Aged dogs (11-12 years) were placed into 4 groups: (1) control/control (C/C); (2) control/VAC (C/V); (3) ENR/control (E/C); and (4) ENR/VAC (E/V) and treated for 20 months. VAC decreased brain Aβ, pyroglutamate Aβ, increased cerebrospinal fluid Aβ 42 and brain-derived neurotrophic factor RNA levels but also increased microhemorrhages. ENR reduced brain Aβ and prevented microhemorrhages. The combination treatment resulted in a significant maintenance of learning over time, reduced Aβ, and increased brain-derived neurotrophic factor mRNA despite increased microhemorrhages; however, there were no benefits to memory. These results suggest that the combination of immunotherapy with behavioral enrichment leads to cognitive maintenance associated with reduced neuropathology that may benefit people with Alzheimer's disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Alzheimer's disease; Brain; Brain-derived neurotrophic factor; Canine; Cerebrovascular; Dog; Immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27776266      PMCID: PMC5154836          DOI: 10.1016/j.neurobiolaging.2016.09.007

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  80 in total

Review 1.  Cerebral microhemorrhage.

Authors:  Anand Viswanathan; Hugues Chabriat
Journal:  Stroke       Date:  2006-01-05       Impact factor: 7.914

Review 2.  MRI of cerebral microhemorrhages.

Authors:  Marisa Kastoff Blitstein; Glenn A Tung
Journal:  AJR Am J Roentgenol       Date:  2007-09       Impact factor: 3.959

3.  Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.

Authors:  David A Costa; Jennifer R Cracchiolo; Adam D Bachstetter; Tiffany F Hughes; Kelly R Bales; Steven M Paul; Ronald F Mervis; Gary W Arendash; Huntington Potter
Journal:  Neurobiol Aging       Date:  2006-05-26       Impact factor: 4.673

Review 4.  Landmark discrimination learning in the dog: effects of age, an antioxidant fortified food, and cognitive strategy.

Authors:  Norton W Milgram; E Head; B Muggenburg; D Holowachuk; H Murphey; J Estrada; C J Ikeda-Douglas; S C Zicker; C W Cotman
Journal:  Neurosci Biobehav Rev       Date:  2002-10       Impact factor: 8.989

5.  Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

6.  Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Authors:  Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 7.  Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review.

Authors:  E Uro-Coste; G Russano de Paiva; C Guilbeau-Frugier; N Sastre; P J Ousset; N A da Silva; V Lavialle-Guillotreau; B Vellas; M-B Delisle
Journal:  Clin Neuropathol       Date:  2010 Jul-Aug       Impact factor: 1.368

8.  Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines.

Authors:  Elizabeth Head; Viorela Pop; Floyd Sarsoza; Rakez Kayed; Tina L Beckett; Christa M Studzinski; Jennifer L Tomic; Charles G Glabe; M Paul Murphy
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

9.  Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

Authors:  Donna M Wilcock; Amyn Rojiani; Arnon Rosenthal; Gil Levkowitz; Sangeetha Subbarao; Jennifer Alamed; David Wilson; Nedda Wilson; Melissa J Freeman; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 10.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches.

Authors:  Carl W Cotman; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more
  5 in total

Review 1.  Environmental influences on development of executive functions in dogs.

Authors:  Maike Foraita; Tiffani Howell; Pauleen Bennett
Journal:  Anim Cogn       Date:  2021-02-21       Impact factor: 3.084

2.  Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.

Authors:  Alex M Helman; Morgan Siever; Katie L McCarty; Ira T Lott; Eric Doran; Erin L Abner; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 3.  Companion animal models of neurological disease.

Authors:  Brittanie Partridge; John H Rossmeisl
Journal:  J Neurosci Methods       Date:  2019-11-13       Impact factor: 2.390

4.  Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank.

Authors:  Michael P Vitek; Joseph A Araujo; Michael Fossel; Barry D Greenberg; Gareth R Howell; Stacey J Sukoff Rizzo; Nicholas T Seyfried; Andrea J Tenner; Paul R Territo; Manfred Windisch; Lisa J Bain; April Ross; Maria C Carrillo; Bruce T Lamb; Rebecca M Edelmayer
Journal:  Alzheimers Dement (N Y)       Date:  2021-01-11

5.  Owner reported sensory impairments affect behavioural signs associated with cognitive decline in dogs.

Authors:  Dóra Szabó; Ádám Miklósi; Enikő Kubinyi
Journal:  Behav Processes       Date:  2018-07-25       Impact factor: 1.777

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.